Bioventus Q2 revenue misses estimates on surgical solutions decline
BVS•Outlook
- Bioventus reaffirms 2026 net sales guidance of $600 mln to $610 mln
- Company maintains 2026 adjusted EPS guidance of $0.75 to $0.79
- Bioventus initiates review of strategic alternatives, including potential sale
Overview
- US medical device maker's Q2 revenue rose 4% but missed analyst expectations
- Adjusted EPS for Q2 rose to $0.22 from $0.21 a year earlier
- Company initiates review of strategic alternatives after receiving acquisition interest
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Miss | $153.20 mln | $155.64 mln (5 Analysts) |
| Q2 Adjusted EBITDA | $35.30 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy". Wall Street's median 12-month price target for Bioventus Inc. is $15.00, about 11.8% above its August 4 closing price of $13.42. The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago.
